Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Florence

Showing results (31-40 of 116) with videos related to

Pageof 12
Sort By:
AIDS Patient Care and Stds|April 19, 2022
Why Do HIV Pre-Exposure Prophylaxis Users Discontinue Pre-Exposure Prophylaxis Care? A Mixed Methods Survey in a Pre-Exposure Prophylaxis Clinic in BelgiumThibaut Vanbaelen, Anke Rotsaert, Bart K M Jacobs, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 12, 2020
Did Pre-exposure Prophylaxis Roll-Out Influence the Epidemic of Rectal Lymphogranuloma Venereum in Belgium? Results From the National Surveillance SystemIrith De Baetselier, Achilleas Tsoumanis, Eric Florence, et al.
International Journal of STD & AIDS|June 18, 2021
Screening for STIs is one of the main drivers of macrolide consumption in PrEP usersThibaut Vanbaelen, Christophe Van Dijck, Irith De Baetselier, et al.
International Journal of STD & AIDS|April 5, 2014
Use of rapid HIV testing in a low threshold centre in Antwerp, Belgium, 2007-2012Kristien Wouters, Katrien Fransen, Greet Beelaert, et al.
Plos One|June 6, 2012
Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patientsEllen Van Gulck, Lotte Bracke, Leo Heyndrickx, et al.
Cytometry. Part B, Clinical Cytometry|February 27, 2016
CD4 results with a bias larger than hundred cells per microliter can have a significant impact on the clinical decision during treatment initiation of HIV patientsGéraldine Daneau, Jozefien Buyze, Djibril Wade, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 13, 2015
Risk factors for HCV acquisition among HIV-positive MSM in BelgiumLudwig Apers, Wim Vanden Berghe, Stéphane De Wit, et al.
AIDS (London, England)|April 15, 2020
Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patientsRakan Nasreddine, Eric Florence, Bernard Vandercam, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 15, 2014
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trialsPablo Tebas, Michael Sension, José Arribas, et al.
AIDS (London, England)|February 1, 2019
In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patientsPieter Pannus, Philipp Adams, Elisabeth Willems, et al.
Pageof 12

Showing results (31-40 of 116) with videos related to

Sort By:
Pageof 12
AIDS Patient Care and Stds|April 19, 2022
Why Do HIV Pre-Exposure Prophylaxis Users Discontinue Pre-Exposure Prophylaxis Care? A Mixed Methods Survey in a Pre-Exposure Prophylaxis Clinic in BelgiumThibaut Vanbaelen, Anke Rotsaert, Bart K M Jacobs, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 12, 2020
Did Pre-exposure Prophylaxis Roll-Out Influence the Epidemic of Rectal Lymphogranuloma Venereum in Belgium? Results From the National Surveillance SystemIrith De Baetselier, Achilleas Tsoumanis, Eric Florence, et al.
International Journal of STD & AIDS|June 18, 2021
Screening for STIs is one of the main drivers of macrolide consumption in PrEP usersThibaut Vanbaelen, Christophe Van Dijck, Irith De Baetselier, et al.
International Journal of STD & AIDS|April 5, 2014
Use of rapid HIV testing in a low threshold centre in Antwerp, Belgium, 2007-2012Kristien Wouters, Katrien Fransen, Greet Beelaert, et al.
Plos One|June 6, 2012
Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patientsEllen Van Gulck, Lotte Bracke, Leo Heyndrickx, et al.
Cytometry. Part B, Clinical Cytometry|February 27, 2016
CD4 results with a bias larger than hundred cells per microliter can have a significant impact on the clinical decision during treatment initiation of HIV patientsGéraldine Daneau, Jozefien Buyze, Djibril Wade, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 13, 2015
Risk factors for HCV acquisition among HIV-positive MSM in BelgiumLudwig Apers, Wim Vanden Berghe, Stéphane De Wit, et al.
AIDS (London, England)|April 15, 2020
Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patientsRakan Nasreddine, Eric Florence, Bernard Vandercam, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 15, 2014
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trialsPablo Tebas, Michael Sension, José Arribas, et al.
AIDS (London, England)|February 1, 2019
In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patientsPieter Pannus, Philipp Adams, Elisabeth Willems, et al.
Pageof 12